WASHINGTON, DC, May 12, 2015 – The Alliance for Regenerative Medicine (ARM), the international organization representing the regenerative medicine and advanced therapies community, continues to expand its presence in Europe with the appointment of Annie Hubert as the new director of European public policy and Caroline Ruggieri as the new director of the organization’s European section.
“We are so pleased to welcome Annie and Caroline to our team,” said Morrie Ruffin, managing director of ARM. “Each possesses a deep understanding of the regenerative medicine and advanced therapies sector in Europe and will be invaluable to the organization as we continue to broaden our efforts internationally.”
Annie Hubert brings over 30 years of experience in European regulatory and government affairs, pricing, reimbursement and market access. Most recently, she served as director of public affairs for the EU-based Alliance for Advanced Therapies (AAT), prior to its membership merger with ARM in October 2014. Previously, Annie was founder and director of Co-ACT, an association of small- and medium-sized enterprises working in advanced therapies in Belgium. In addition, Annie has held management roles at Amgen, Warner-Lambert (now Pfizer); Pharmacia (now Pfizer); and Beecham Research Laboratories (now GSK). She has a Masters of Pharmacy from the Catholic University of Louvain in Belgium. She is currently based in Brussels, Belgium.
Caroline Ruggieri will be leading ARM’s European section, addressing the needs and priorities of ARM’s EU-based member companies. She brings an extensive understanding of international project management and business development to ARM. Caroline is also the founder and managing director of Access Life Sciences, a Netherlands-based consultancy firm. Previously, Caroline served as manager for international relations at the Biotechnology Industry Organization (BIO) in Washington, D.C. for nearly a decade, focused on business development, strategic alliances and policy advocacy. Prior to BIO, Caroline performed health services research and policy analysis for the Medical Technology & Practice Patterns Institute, also in Washington, D.C. She holds a B.A. in Spanish and Government from Georgetown University and is based in The Netherlands.
About the Alliance for Regenerative Medicine
The Alliance for Regenerative Medicine (ARM) is an international multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine worldwide. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, D.C. to specifically represent the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today, ARM has more than 200 members and is the leading global advocacy organization in this field. To learn more about ARM or to become a member, visit http://www.alliancerm.org.